Stocks analysis

ABBV vs AFL Stock Comparison

Scores Breakdown

Metric ABBV AFL
📈 Growth 26/30 6/30
💰 Profitability 18/20 18/20
🏦 Financial Health 6/20 15/20
💵 Valuation 12/20 12/20
⚠️ Risk (lower is better) 8/10 7/10
Overall Score 64/100 54/100

Side-by-Side Summaries

ABBV Analysis AFL Analysis

📈 Growth & Financial Trajectory

Over the eight quarters, Revenues rose from about $14.46B (2024-Q2) to about $16.99B (2026-Q2). Net Income expanded from about $1.31B to about $3.62B, with quarterly fluctuations (notably a dip in 2025-Q2 before a robust rebound by 2026-Q2).

💰 Margins & Cash Flow

Gross Profit was strong, and implied gross margins around the mid-to-high 70s percent, peaking around 75% in late 2025 and staying near that level in 2026-Q2 (e.g., $12.7B gross profit on $16.99B revenue). Operating income remained positive across the period, supporting a healthy but fluctuating margin structure. Net Cash Flow From Operating Activities stayed positive in all quarters, with peaks near $5.15B in 2025-Q4 and around $3.44B in 2026-Q2; investing and financing activities contributed to occasional cash outflows, resulting in negative total cash flow in several quarters.

🛡️ Balance Sheet & Liquidity

Total assets ranged around $134-141B; liabilities aligned with asset base, yielding negative Equity in several periods (e.g., -$5.89B in 2026-Q2), signaling solvency risk despite strong operating cash flow. Current liabilities remain substantial, but liquidity from operating cash flow partially offsets near-term obligations.

⚠️ Key Drivers & Risks

  • Drivers: Robust, diversified dermatology/immunology portfolio with steady cash generation; payer pricing power.
  • Risks: Negative equity/leverage sensitivity to debt refinancing; regulatory/payer pressures and potential patent/exclusivity shifts.

📈 Growth & Financial Trajectory

Eight quarters show a revenue path from $5.403B (2024 Q3) to $4.117B (2026 Q2). A trough occurred in 2025 Q1 with $4.16B rev and $29M net income. Revenues then recovered to the high 4.7–4.9B range in 2025 H2, before easing again to $4.12B in 2026 Q2. Net income moved from $1.902B (2024 Q3) to $0.825B (2026 Q2), with a dip to $29M in 2025 Q1. Overall, the trend is negative on revenue and earnings, but several quarters display strong operating performance (notably 2024 Q3 and late-2025/2026).

💰 Margins & Cash Flow

Operating margins were robust on several quarters, averaging in the mid-60s percent, peaking around 75% in 2024 Q3 and hovering near 70% in late 2025–2026; a trough around 40–41% occurred in 2025 Q2. Cash flow from operations remained positive across periods (e.g., $315M in 2024 Q4, $1.27B in 2025 Q3, $112M in 2026 Q2), while investing/financing swings produced occasional negative free cash flow (notably 2025 Q1 and 2026 Q1).

🛡️ Balance Sheet & Liquidity

Current assets consistently exceed current liabilities (e.g., 2026 Q2: Current Assets $115.96B vs Current Liabilities $85.65B). Total assets run in the $116–$125B range with equity around $28–$30B, indicating a solid reserve position given insurer-liability balances. Leverage remains typical for an insurance franchise, with ample liquidity cushions.

⚠️ Key Drivers & Risks

  • Drivers: Stable insurance premium streams and investment income support, with favorable rate environments aiding capital generation.
  • Risks: Earnings volatility from reserve dynamics and regulatory shifts; sensitivity to interest-rate changes and macro cycle could compress margins during downturns.